Drug levels and antibodies including infliximab, adalimumab, vedolizumab and ustekinumab

EPIC

Infliximab, adalimumab, vedolizumab and ustekinumab

Section

Immunology

Clinical indications

Monitors drug levels and presence of antibodies

Specimen requirement

1ml serum / serum gel

Dispatch and handling instructions

Sent to Royal Devon and Exeter

Turnaround time

40 days

Synonym

Not applicable

Is it IS0 15189 accredited?

Yes: Infliximab, adalimumab

No (research): vedolizumab and ustekinumab